Abstracts tagged "Angiogenesis and rheumatoid arthritis (RA)"

Abstract Number: 1066 • 2018 ACR/ARHP Annual Meeting
Tocilizumab Effect on Serum Angiogenic Factors in Rheumatoid Arthritis Patients
Muna Elias¹, Michal Amit Rahat², Joy Feld¹, Itzhak Rosner³, Lisa Kaly⁴, Idit Lavi⁵, Tal Gazitt⁶ and Devy Zisman⁷, ¹Rheumatology Unit Carmel Medical Center, Haifa, Israel, ²Immunotherapy laboratory, Carmel medical center, Haifa, Israel, ³Rheumaoloy Unit, Bnai Zion Medical Center, Haifa, Israel, ⁴Rheumatology unit, Bnai-Zion Medical Center, Haifa, Israel, ⁵Epidemiology Unit Carmel Medical Center, Haifa, Israel, ⁶Rheumatology unit, Carmel medical center, Haifa, Israel, ⁷Rheumatology Unit, Carmel Medical Center, Haifa, Israel
Background/Purpose: Several inducers of angiogenesis have been shown to play a central role in rheumatoid arthritis (RA) pathogenesis: VEGF (Vascular Endothelial Growth Factor), EMMPRIN (Extracellular…
Abstract Number: 1062 • 2018 ACR/ARHP Annual Meeting
Linking Systemic Angiogenic Markers to Synovial Vascularization in Rheumatoid Arthritis
Agathe Leblond¹, Sonia Pezet¹, Anne priscille Trouvin², Muriel Elhai², Virginie Gonzalez¹, Yannick Allanore³ and Jérôme Avouac², ¹Université Paris Descartes, Sorbonne Paris Cité, INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France, Paris, France, ²Université Paris Descartes, Sorbonne Paris Cité, Service de Rhumatologie A, Hôpital Cochin, Paris, France, Paris, France, ³Service de Rhumatologie A, Hôpital Cochin, Paris, France
Background/Purpose: Neoangiogenesis is a crucial event to promote the development of the hyperplasic proliferative pathologic synovium in Rheumatoid arthritis (RA). Ultrasound (US) is sensitive for…
Abstract Number: 2576 • 2016 ACR/ARHP Annual Meeting
uPAR Promotes Tumor-like Biologic Role of Fibroblast-like Synoviocytes through PI3K/Akt Signaling Pathway in Patients with Rheumatoid Arthritis
Yan Liu¹, Yunfeng Pan² and Song Guo Zheng³, ¹Center for Clinic Immunology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, China, ²Rheumatology, third affiliated hospital of Sun Yat-sen Universtiy, Guangzhou, China, ³Medicine/Rheumatology, Penn State Hershey Medical Center, Hershey, PA
Background/Purpose: Urokinase-type plasminogen activator receptor (uPAR), is a multi-functional receptor on cell surface, widely present in endothelial cells, fibroblasts, and a variety of malignant cells.…
Abstract Number: 10 • 2015 ACR/ARHP Annual Meeting
CD13/Aminopeptidase N Contributes to Angiogenesis and Monocyte Chemotaxis in Rheumatoid Arthritis
Rachel Morgan¹, M. Asif Amin¹, Jeffrey Ruth¹, Gautam Edhayan², Stephanie Rasmussen³ and David A. Fox¹, ¹Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Aminopeptidase N (CD13, EC 3.4.11.2) is a metalloproteinase expressed on the surface of fibroblast like synoviocytes (FLS), and as a soluble protein in serum…
Abstract Number: 17 • 2015 ACR/ARHP Annual Meeting
Disentangling the Role of Hypoxia-Inducible Factor 1 and 2 in the Adaption Process of Human Microvascular Endothelial Cells to Pathophysiological Hypoxia
Martin Hahne¹, Peggy Kunath², Mathias Mursell³, Cindy Strehl², Gerd Burmester⁴, Frank Buttgereit² and Timo Gaber², ¹Miltenyi Biotec GmbH, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Angiogenesis is a prominent feature of the pathogenesis of RA. Although new blood vessels deliver oxygen to the augmented inflammatory cell mass, the neovascular…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].